Aura Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Accumulated · Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’ | |||||||||||
| Shares · Amount · Capital · Deficit · Loss Amount · Equity | |||||||||||
| Balance, December 31, 2023 | 49,350,788 | $— | $512,617 | $(287,308) | $539 | $225,848 | |||||
| Stock-based compensation expense | — | — | 2,909 | — | — | 2,909 | |||||
| ESPP issuance | 12,314 | — | 95 | — | — | 95 | |||||
| Stock option exercises | 51,180 | — | 158 | — | — | 158 | |||||
| Vesting of restricted stock | 90,123 | — | — | — | — | — | |||||
| Unrealized gain on marketable securities | — | — | — | — | (521) | (521) | |||||
| Net loss | — | — | — | (19,706) | — | (19,706) | |||||
| Balance, March 31, 2024 | 49,504,405 | — | 515,779 | (307,014) | 18 | 208,783 | |||||
| Stock-based compensation expense | — | — | 3,126 | — | — | 3,126 | |||||
| Employee stock purchase plan | — | — | — | — | — | ||||||
| Stock option exercises | 24,245 | — | 83 | — | — | 83 | |||||
| Vesting of restricted stock | 54,708 | — | — | — | — | — | |||||
| Unrealized gain on marketable securities | — | — | — | — | (201) | (201) | |||||
| Net loss | — | — | — | (20,337) | — | (20,337) | |||||
| Balance, June 30, 2024 | 49,583,358 | $— | $518,988 | $(327,351) | $(183) | $191,454 | |||||
| Additional · Accumulated · Total | |||||||||||
| Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’ | |||||||||||
| Shares · Amount · Capital · Deficit · Loss Amount · Equity | |||||||||||
| Balance, December 31, 2022 | 37,771,918 | $— | $406,555 | $(210,900) | $(72) | $195,583 | |||||
| Stock-based compensation expense | — | — | 1,913 | — | — | 1,913 | |||||
| ESPP issuance | 6,635 | — | 56 | — | — | 56 | |||||
| Stock option exercises | 21,549 | — | 145 | — | — | 145 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 27 | 27 | |||||
| Net loss | — | — | — | (17,466) | — | (17,466) | |||||
| Balance, March 31, 2023 | 37,800,102 | — | 408,669 | (228,366) | (45) | 180,258 | |||||
| Stock-based compensation expense | — | — | 1,931 | — | — | 1,931 | |||||
| Issuance of common stock under ATM facility, net of issuance costs of $35 | 169,200 | — | 2,065 | — | — | 2,065 | |||||
| Stock option exercises | 117,304 | — | 660 | — | — | 660 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (178) | (178) | |||||
| Net loss | — | — | — | (18,299) | — | (18,299) | |||||
| Balance, June 30, 2023 | 38,086,606 | $— | $413,325 | $(246,665) | $(223) | $166,437 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.